HIV Infection

Infectious Diseases
51
Pipeline Programs
17
Companies
50
Clinical Trials
1 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
7
0
11
27
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1381%
Vaccine
319%
+ 52 programs with unclassified modality

On Market (4)

Approved therapies currently available

GS
EMTRIVAApproved
emtricitabine
Gilead Sciences
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]oral2005
GS
ODEFSEYApproved
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide
Gilead Sciences
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]oral2016
Bristol Myers Squibb
REYATAZApproved
atazanavir
Bristol Myers Squibb
oral2003
GS
VITEKTAApproved
elvitegravir
Gilead Sciences
oral2014

Competitive Landscape

16 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
15 programs
3
4
6
All licensed antiretroviral medicationsPhase 41 trial
Regimen:BIC+FTC+TAFPhase 41 trial
TenofovirPhase 4Small Molecule1 trial
Treatment simplificationPhase 41 trial
emtricitabinePhase 4
+10 more programs
Active Trials
NCT06900829Recruiting5,200Est. Feb 2030
NCT01769456Completed78Est. Nov 2016
NCT03120494Unknown75Est. Nov 2019
+12 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
13 programs
3
1
4
Artemether/LumefantrinePhase 41 trial
Atazanavir/ritonavirPhase 4Small Molecule
Highly active antiretroviral therapyPhase 41 trial
Transdermal estradiol gelPhase 41 trial
Emtricitabine/tenofovir disoproxil fumaratePhase 3
+8 more programs
Active Trials
NCT00851799CompletedEst. Jun 2013
NCT02602262CompletedEst. Jun 2023
NCT02140944CompletedEst. Oct 2022
+7 more trials
M&
Merck & Co.RAHWAY, NJ
11 programs
2
3
2
All licensed antiretroviral medicationsPhase 4
once daily minimum 3-drug regimen of anti-retroviral medicationsPhase 41 trial
DOR/ISLPhase 35 trials
Efavirenz-Tenofovir-EmtricitabinePhase 3
Reformulated RaltegravirPhase 3Small Molecule1 trial
+6 more programs
Active Trials
NCT01042808Completed996Est. May 2014
NCT00944879Unknown1,400Est. Feb 2011
NCT01065792Completed728Est. Feb 2014
+9 more trials
Abbott
AbbottABBOTT PARK, IL
10 programs
1
5
All licensed antiretroviral medicationsPhase 4
LopinavirPhase 4Small Molecule1 trial
Lopinavir/RitonavirPhase 4Small Molecule1 trial
MonotherapyPhase 45 trials
atazanavirPhase 4Small Molecule1 trial
+5 more programs
Active Trials
NCT00951795Withdrawn0Est. Sep 2009
NCT00262717Completed338Est. Jul 2006
NCT01103596Completed94Est. Jul 2009
+12 more trials
Bristol Myers Squibb
8 programs
1
3
All licensed antiretroviral medicationsPhase 4
Atazanavir/ritonavirPhase 4Small Molecule1 trial
once daily minimum 3-drug regimen of anti-retroviral medicationsPhase 4
Emtricitabine/tenofovir disoproxil fumaratePhase 3
Blood test: genotype testingN/A
+3 more programs
Active Trials
NCT00162227No Longer AvailableEst. Dec 2010
NCT00162188No Longer AvailableEst. Dec 2010
NCT00096746Completed200Est. Sep 2006
+1 more trials
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
Estradiol Vaginal InsertPhase 41 trial
Active Trials
NCT04079218Completed60Est. Aug 2023
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
FUZEON [enfuvirtide]Phase 41 trial
Active Trials
NCT00100984Terminated8Est. Jul 2005
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Lopinavir/RitonavirPhase 4Small Molecule1 trial
Active Trials
NCT02581202Completed216Est. May 2017
Dynavax Technologies
Dynavax TechnologiesCA - Emeryville
1 program
1
HEPLISAV-BPhase 31 trial
Active Trials
NCT04193189Completed638Est. Aug 2024
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
1
MVA-nefPhase 21 trial
Active Trials
NCT00189930Completed77Est. Dec 2006
Genentech
GenentechCA - Oceanside
1 program
1
PanobinostatPhase 1/2Small Molecule
Theravectys
TheravectysFrance - Paris
1 program
1
THV01-1Phase 1/21 trial
Active Trials
NCT02054286CompletedEst. Feb 2019
Novartis
NovartisBASEL, Switzerland
1 program
1
HIV-1 Tat/delta-V2 Env combined vaccinePhase 1Vaccine1 trial
Active Trials
NCT01441193Terminated11Est. Feb 2014
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
N-803Phase 11 trial
Active Trials
NCT04340596Active Not RecruitingEst. Dec 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Blood test: genotype testingN/A
Reviva Pharmaceuticals
1 program
HIV-1 plasma RNA Genotyping secuencing by Sanger techniqueN/A1 trial
Active Trials
NCT03957369CompletedEst. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Allergy TherapeuticsTransdermal estradiol gel
Gilead SciencesRegimen:BIC+FTC+TAF
AbbottMonotherapy
Novo NordiskEstradiol Vaginal Insert
Gilead SciencesTenofovir
Gilead SciencesTenofovir
Gilead SciencesTenofovir
Gilead SciencesTreatment simplification
Gilead SciencesTenofovir
Allergy TherapeuticsArtemether/Lumefantrine
Bristol Myers SquibbAtazanavir/ritonavir
Allergy TherapeuticsHighly active antiretroviral therapy
Gilead SciencesAll licensed antiretroviral medications
AbbottMonotherapy
AbbottLopinavir

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 16,687 patients across 50 trials

NCT06856174Allergy TherapeuticsTransdermal estradiol gel

Menopausal HT for Women Living With HIV (HoT)

Start: Jan 2026Est. completion: Sep 2027
Phase 4Not Yet Recruiting
NCT06830668Gilead SciencesRegimen:BIC+FTC+TAF

Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation

Start: Feb 2025Est. completion: Dec 2026250 patients
Phase 4Not Yet Recruiting

Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

Start: Jul 2022Est. completion: Aug 20281,656 patients
Phase 4Recruiting
NCT04079218Novo NordiskEstradiol Vaginal Insert

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

Start: Sep 2020Est. completion: Aug 202360 patients
Phase 4Completed

Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B

Start: Nov 2016Est. completion: Nov 201975 patients
Phase 4Unknown

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

Start: Dec 2015Est. completion: May 202874 patients
Phase 4Active Not Recruiting

PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5

Start: Oct 2014Est. completion: Jun 201652 patients
Phase 4Completed
NCT02199613Gilead SciencesTreatment simplification

Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy

Start: Oct 2014Est. completion: Feb 201710 patients
Phase 4Completed

Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

Start: Mar 2012Est. completion: Jun 2018200 patients
Phase 4Completed
NCT01728961Allergy TherapeuticsArtemether/Lumefantrine

Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy

Start: Feb 2012Est. completion: Mar 2014
Phase 4Terminated

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

Start: Oct 2010Est. completion: Dec 20111 patients
Phase 4Terminated
NCT00955968Allergy TherapeuticsHighly active antiretroviral therapy

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

Start: Jan 2010Est. completion: Aug 2016
Phase 4Completed
NCT00867048Gilead SciencesAll licensed antiretroviral medications

Strategic Timing of Antiretroviral Treatment

Start: Apr 2009Est. completion: Jul 20224,688 patients
Phase 4Completed

Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy

Start: Dec 2008Est. completion: Sep 201288 patients
Phase 4Completed

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin

Start: Nov 2008Est. completion: Dec 201230 patients
Phase 4Completed

Safety and Efficacy Study of Switching From Epzicom to Truvada

Start: Jul 2008Est. completion: Apr 2011312 patients
Phase 4Completed

Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r

Start: Feb 2008Est. completion: Oct 201268 patients
Phase 4Completed

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

Start: Apr 2007Est. completion: Sep 200819 patients
Phase 4Terminated

Anti-Retrovirals for Kaposi's Sarcoma

Start: Apr 2007Est. completion: Jul 2012224 patients
Phase 4Completed

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

Start: Jan 2005Est. completion: Dec 201392 patients
Phase 4Completed
NCT00100984RocheFUZEON [enfuvirtide]

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

Start: Jul 2004Est. completion: Jul 20058 patients
Phase 4Terminated
NCT00214435Merck & Co.once daily minimum 3-drug regimen of anti-retroviral medications

Once Daily 3TC, Efavirenz and ddI for HIV Infection

Start: May 2004120 patients
Phase 4Unknown

Tenofovir in HIV/HBV Coinfection

Start: Jan 2004Est. completion: Jan 200736 patients
Phase 4Completed

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Start: Jul 2003180 patients
Phase 4Terminated
NCT00234975AbbottLopinavir/Ritonavir

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

Start: Oct 2002Est. completion: Jan 200886 patients
Phase 4Completed

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Start: Mar 2023Est. completion: Sep 2028641 patients
Phase 3Active Not Recruiting

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Start: Feb 2023Est. completion: Jul 2028553 patients
Phase 3Active Not Recruiting

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Start: Dec 2020Est. completion: Aug 2024638 patients
Phase 3Completed

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

Start: Feb 2020Est. completion: Aug 2024672 patients
Phase 3Completed

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Start: Feb 2020Est. completion: Feb 2025643 patients
Phase 3Completed
NCT02131233Merck & Co.Reformulated Raltegravir

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Start: May 2014Est. completion: Dec 2016802 patients
Phase 3Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Start: Nov 2010Est. completion: Oct 2014482 patients
Phase 3Completed
NCT00936195Gilead SciencesEfavirenz-Tenofovir-Emtricitabine

Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial

Start: Jan 2010Est. completion: Jun 20130
Phase 3Withdrawn
NCT00811954Gilead SciencesEmtricitabine/tenofovir disoproxil fumarate

Comparative Study of Three NNRTI-Sparing HAART Regimens

Start: May 2009Est. completion: Jun 20131,814 patients
Phase 3Completed

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Start: Jul 2008Est. completion: Apr 2015724 patients
Phase 3Completed

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy

Start: Feb 2007Est. completion: Dec 201060 patients
Phase 3Unknown

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

Start: Feb 2007Est. completion: Dec 201050 patients
Phase 3Unknown
NCT00234910AbbottTenofovir DF

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

Start: Jan 2005Est. completion: Jun 2008152 patients
Phase 3Completed

Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Start: Jun 2004Est. completion: Dec 200640 patients
Phase 3Completed
NCT00043966AbbottTenofovir DF

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

Start: Jul 2002200 patients
Phase 3Completed

Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services

Start: Oct 2012Est. completion: Dec 2015372 patients
Phase 2/3Completed

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

Start: Nov 2020Est. completion: Jan 202342 patients
Phase 2Completed
NCT01601626Allergy TherapeuticsStandard-dose Lopinavir/Ritonavir

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

Start: Jul 2013Est. completion: Jun 2017
Phase 2Terminated

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

Start: Mar 2013Est. completion: Nov 201678 patients
Phase 2Completed

Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

Start: Nov 2009Est. completion: Jan 2017
Phase 2Completed

Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)

Start: Oct 2006Est. completion: Dec 200972 patients
Phase 2Completed

Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

Start: Mar 2006Est. completion: Oct 2010106 patients
Phase 2Completed

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

Start: Apr 2005Est. completion: Dec 200677 patients
Phase 2Completed

Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue

Start: Feb 2003Est. completion: Feb 2006100 patients
Phase 2Completed
NCT00038220AbbottTenofovir DF

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Start: Jul 200040 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

11 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 16,687 patients
17 companies competing in this space